| |
References
1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling
thymoma. Cancer1956; 9: 822-30.
2. Cronin DM, Warnke RA. Castleman disease an update on classification and the spectrum of
associated lesions. Adv Anat Pathol 2009; 16: 236-46.
3. Nakakura E. Retroperitoneal/abdominal masses [Internet]. 2010[cited 2017 Mar 22]. Available from
www.uscfcmc.com>slides>MSU1001.pdf.
4. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full
spectrum of Castleman disease: 273 patients studied over 20 years. British Journal of Hematology
2018; 180(2): 206-16.
5. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404
published cases. Annals of surgery 2012; 255(4): 677-84.
6. Casper C. The etiology and management of Castleman disease at 50 years. Translatiing
pathophysiology to patient care. Br J Haematol 2005; 129(1): 3-17.
7. Shin DY, Jeon YK, Hong YS, Kim TM, Lee SH, Kim DW, et al. Clinical dissection of multicentric
Castleman disease. Leukemia & Lymphoma 2011; 52(8): 1517-22.
8. จักราวดี จุฬามณี, อานุภาพ เลขะกุล. Case discussion I. จุลสารโรคมะเร็งต่อมน้ำเหลือง 2558; (2): 17-
20.
9. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systemic review of 404
published cases. ANN Surg. 2012; 255(4): 677-84.
10. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph
node hyperplasia of the mediastinum and other locations. Cancer 1972; 29(3): 670-83.
11. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasak K, et al. Pathogenic
significance of interleukin-6(IL-6/bsf-2) in Castleman’s disease. Blood1989; 47(4): 1360-7.
12. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Damme JV, et al.
Interleukin-6 gene expression in Castlemas’s disease. Blood 1991; 78(11): 2923-30.
13. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D. International, evidence-based consensus
diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;
129(12): 1646-57.
14. Talat N, Schulte KM. Castlemam’s disease: systematic analysis of 416 patients from the literature.
Oncologist 2011; 16(9): 1316-24.
15. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD, et al. Treatment of unicentric
and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670. |
|
.jpg)
